Dergiler / Medicine Science / 2020 / Cilt: 9 - Sayı: 1

Evaluation of helicobacter pylori eradication therapy with serum myeloperoxidase levels

Sayfa
39–44
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Consequently, MPO levels may be determinant in monitoring the effectiveness of H. pylori eradication therapy

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Helicobacter pylori (H. pylori) is associated with chronic gastritis, peptic ulcers, and gastric adenocarcinomas.
📊
Temel Bulgular & Veri:One hundred seven (107) patients were enrolled in the study.
💡
Sonuç & Katkı:Consequently, MPO levels may be determinant in monitoring the effectiveness of H. pylori eradication therapy
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Helicobacter pylori (H. pylori) is associated with chronic gastritis, peptic ulcers, and gastric adenocarcinomas. H. pylori-infected patients produce reactive oxygen species (ROS) in gastric mucosa. Production of ROS induces the myeloperoxidase (MPO) activity. This study aims the determination of the relationship between MPO level and H. pylori infection and eradication therapy. One hundred seven (107) patients were enrolled in the study. H. pylori were detected by histopathological examination of the specimens. The patients were divided into two groups: Group 1 (H. pylori-negative), Group 2 (H. pylori-positive). The tissue MPO activity and serum MPO levels of these two groups were compared. Patients with H. pylori infection received eradication therapy. Post-treatment serum MPO levels were also compared. Histopathological examination revealed that 28(26.2%) patients were H. pylori-negative (Group 1), whereas 79(73.8%) patients were H. pylori-positive (Group 2). Tissue MPO activity of the groups was compared, and a significant difference was found between two groups, 0.5(1) and 2(1), respectively (p<0.001). There was no significant difference between the groups in terms of serum MPO levels 2.19(1.91) ng/mL and 2.69(2.45) ng/mL, respectively (P=0.266). There was a significant difference between pre-treatment and post-treatment serum MPO levels after eradication therapy 2.69(2.45) and 1.26(2.36), respectively (p=0.002). Consequently, MPO levels may be determinant in monitoring the effectiveness of H. pylori eradication therapy

🔖

Bu Makaleye Atıf Yap

GUNDUZOZ, M., IRİTAS, S. B., GURESCİ, S., BUYUKSEKERCİ, M., OZAKİNCİ, O. G., NAZLİGUL, Y. (2020). Evaluation of helicobacter pylori eradication therapy with serum myeloperoxidase levels. Medicine Science, Cilt: 9 - Sayı: 1, 39–44. https://ajindex.com/articles/276835

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Özden A. Helicobacter pylori. Güncel Gastroenteroloji. 2006;10:287-91
  2. International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC monographs on the evaluation of carcinogenic risks to humans, 61. Lyon. France: IARC, 1994
  3. Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis, World J. Gastroint. Oncol. 2015;7:455
  4. Nemattalab M, Shenagari M, Taheri M, et al. Co-expression of interleukin-17a molecular adjuvant and prophylactic helicobacter pylori genetic vaccine could cause sterile ı̇mmunity ı̇n treg suppressed mice. Cytokine. 2019;126:154866 5. Terasawa T, Hamashima C, Kato K et al. H.Helicobacter pylori eradication treatment for gastric carcinoma prevention ı̇n asymptomatic or dyspeptic adults: systematic review and bayesian meta-analysis of randomised controlled trials. H.Bmj Open. 2019;9:E026002 6. Mégraud F. Helicobacter pylori, gastric inflammation and its consequences. Ann Pharm Fr. 2003;61:282-7
  5. Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annu Rev Pathol. 2006;1:63-96
  6. Pasceri V, Patti G, Cammarota G et al. Virulent strains of Helicobacter pylori and vascular diseases: a meta-analysis. Am Heart J. 2006;151:1215-22
  7. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process – first American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735-40
  8. Roe I, Nam S, Kim J. et al. Association of the myeloperoxidase –463G!A polymorphism with development of atrophy in Helicobacter pylori-infected gastritis. Am J Gastroenterol. 2002;97:1629-34
  9. Ohnishi S, Murata M, Kawanishi S. DNA damage induced by hypochlorite and hypobromite with reference to inflammation-associated carcinogenesis. Cancer Lett. 2002;178:37–42
  10. Suzuki M, Miura S, Suematsu M. et al. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury. Am J Physiol.1992;263:719-25
  11. Polenghi A, Bossi F, Fischetti F. et al. The neutrophil activating protein of helicobacter pylori crosses endothelia to promote neutrophil adhesion in vitro. J Immunol. 2007;178:1312-20
  12. Miyasaki KT, Vilson ME, Genco RJ. Klinig of actinobacillus actinomycetemcomitans by the human neutrophil myeloperoxidase-hydrogen peroxide-chloride system. Infect Immun. 1986;53:161-5
  13. Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprote